01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
18:55 , Aug 31, 2018 |  BC Week In Review  |  Company News

Emergent BioSolutions acquires opioid overdose company

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire opioid overdose and addiction company Adapt Pharma Ltd. (Dublin, Ireland) for $635 million up front, comprising $575 million in cash and $60 million in stock. Adapt shareholders...
23:19 , Aug 28, 2018 |  BC Extra  |  Company News

Emergent BioSolutions acquires opioid overdose company

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire opioid overdose and addiction company Adapt Pharma Ltd. (Dublin, Ireland) for $635 million up front, comprising $575 million in cash and $60 million in stock. Adapt shareholders...
02:19 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Naloxone Hydrochloride Nasal Spray regulatory update

EMA accepted for review an MAA from Adapt for Naloxone Hydrochloride Nasal Spray to treat opioid overdose. Adapt markets the opioid antagonist nasal spray in the U.S. as Narcan Nasal Spray. Adapt has worldwide rights...
23:41 , Feb 21, 2017 |  BC Extra  |  Company News

Amphastar falls on CRL for intranasal naloxone

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) dropped $4.20 (23%) to $14.20 on Tuesday after it said it received a complete response letter from FDA for Naloxone Hydrochloride 2mg/0.5mL Nasal Spray, under review for the emergency treatment of...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Narcan naloxone regulatory update

Adapt said Canada approved Narcan naloxone nasal spray for the emergency treatment of known or suspected opioid overdose. FDA approved Narcan last year. Adapt has worldwide rights to develop and commercialize the opioid antagonist nasal...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Narcan naloxone regulatory update

FDA approved Narcan naloxone nasal spray for the emergency treatment of known or suspected opioid overdose. Adapt has worldwide rights to develop and commercialize the opioid antagonist nasal spray from Lightlake. The NDA was approved...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Narcan naloxone regulatory update

FDA accepted and granted Priority Review to an NDA from Adapt for Narcan naloxone Nasal Spray to treat opioid overdose. The PDUFA date is in early 2016. Adapt has worldwide rights to develop and commercialize...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Narcan intranasal naloxone regulatory update

Adapt submitted an NDA to FDA for Narcan naloxone nasal spray to treat opioid overdose. The opioid antagonist nasal spray has Fast Track designation in the U.S. Adapt has worldwide rights to develop and commercialize...